Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00369174
Other study ID # NCI-2012-02968
Secondary ID 2005-0485N01CN35
Status Completed
Phase Phase 2
First received August 24, 2006
Last updated February 12, 2013
Start date June 2006

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia


Description:

PRIMARY OBJECTIVES:

I. To determine the rate of clinical response of oral premalignant lesions (OPL) to 12 weeks of therapy with rosiglitazone (Avandia), 8 mg daily, defined as greater than or equal to 50% reduction in the measured product of perpendicular dimension of the target lesion, or improvement in the degree of dysplasia.

SECONDARY OBJECTIVES:

I. To determine the rate and degree of change of putative biomarkers of rosiglitazone efficacy including:

COX-2, cyclin D1, Ki-67, p21/waf1, PPAR gamma, K1 cytokeratin, involucrin, transglutaminase expressions, and TUNEL.

II. To estimate the correlation between DNA ploidy measurements in OPL with clinical response and or response of biomarkers to rosiglitazone therapy, and to estimate the efficacy of rosiglitazone therapy to normalize aberrant DNA ploidy in OPL.

III. To thoroughly assess smoking patterns among trial participants and to examine the relationship of smoking to treatment response.

IV. To assess the safety of this agent in short-term use in this population.

OUTLINE: This is a multicenter, open-label, nonrandomized study.

Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed at 1 week.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date
Est. primary completion date August 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males or females with a suspected or histologically confirmed index oral premalignant lesion (excluding carcinoma in situ), 12mm or greater in size that has not been biopsied in the past 6 weeks; each index lesion must be either a:

- dysplastic measurable leukoplakia or erythroplakia in the oral cavity or accessible oropharynx, or

- hyperplastic leukoplakia of high-risk sites, lateral and ventral tongue and floor of mouth

- The subject's life expectancy is > 12 weeks and Karnofsky performance score is 70-100%

- Hemoglobin and hematocrit levels above the lower limit of normal

- White blood cells >= 3,000/uL

- Platelets >= 125,000/uL

- Total bilirubin =< 1.5 x ULN

- AST (SGOT)/ALT (SGPT) =< 1.5 x ULN

- BUN and serum creatinine =< 1.5 x ULN

- LDH =< 1.5 x ULN

- If the subject is female and of childbearing potential (women are considered not of childbearing potential if they are at least two years postmenopausal and/or surgically sterile), she:

- has been using adequate contraception (abstinence, IUD, birth control pills, or spermicidal gel with diaphragm or condom) since her last menses and will use adequate contraception during the study, AND

- is not lactating, AND

- has a documented negative serum pregnancy test within 14 days prior to randomization

- The subject has discontinued any other oral cancer chemopreventive therapy at least 12 weeks prior to the Baseline visit and all toxicities have been fully resolved; daily aspirin is permitted

- The subject is willing and able to fully participate for the duration of the study

- If applicable, the subject has been counseled on smoking cessation

- The effects of rosiglitazone (Avandia) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, and because rosiglitazone has been associated with fetal death and growth retardation in rats and rabbits and placental pathology in rats, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately and will be removed from the trial

- Ability to understand and the willingness to sign a written informed consent document

- The subject is of New York Heart Association (NYHA) Class 1 to 4 cardiac status

Exclusion Criteria:

- The subject has active cancer or carcinoma in situ of the head and neck

- The subject has a contraindication to biopsy

- The subject has any history of congestive heart failure, any history of myocardial infarction, angina, or coronary artery disease within the past 6 months, or active cardiac disease

- The subject exhibits clinical evidence of active liver disease, history of chronic liver disease or edema

- The subject currently receives insulin, sulfonylurea or metformin (doses of rosiglitazone greater than 4 mg daily in combination with these therapies are not currently indicated; because this protocol uses the maximum recommended dose of 8 mg daily, subjects on insulin, sulfonylurea or metformin will be ineligible for participation in this trial); the subject is currently receiving thiazolidinediones; the subject is a diabetic not on treatment or hyperglycemic (has a random blood glucose level > 200 mg/dl); the subject has diabetic macular edema

- The subject is currently receiving medical therapy for dysregulated blood sugar

- The subject has experienced jaundice with RezulinĀ® (troglitazone)

- The subject has known hypersensitivity to rosiglitazone, Avandia, or any of its components

- The subject has a history of colorectal cancer, familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC)

- The subject has a history of invasive cancer within the past 18 months (excluding non-invasive bladder cancer, non-melanoma skin cancer and in situ cervical cancer); subjects (excluding those with a history of colorectal cancer, FAP or HNPCC) who received curative treatment and have shown no evidence of recurrence for 18 months will be eligible

- The subject has had chemotherapy, immunotherapy, hormonal therapy (other than HRT for menopause), or radiation therapy within 18 months of the Baseline visit

- The subject will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT for menopause), or immunotherapy during the time of study

- The subject has received any investigational medication within 30 days of the Baseline visit or is scheduled to receive an investigational drug during the course of the study

- The subject participated in the study previously and was withdrawn

- The subject is pregnant or nursing

- Subjects who have had the study drug prior to this study

- The subject has uncontrolled intercurrent illness including: ongoing or active infection, HIV, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
rosiglitazone maleate
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects who show complete or partial response in either clinical or histological outcomes Estimated together with 95% confidence interval. The confidence interval will be constructed using exact binomial confidence intervals (rather than the normal approximation). 12 weeks No
Secondary Tissue expressions of COX-2, cyclin D1, Ki-67, p21/waf1, PPAR gamma, K1 cytokeratin, involucrin, and transglutaminase, and tissues levels of apoptosis (assessed using TUNEL) Summarized at each time point using summary statistics such as the mean, median, and range. The changes in levels of these biomarkers will also be explored with similar summary statistics and with graphical methods as well. 12 weeks No
Secondary Tissue DNA ploidy 12 weeks No
Secondary Smoking and alcohol use Assessed descriptively. Fisher's exact test may be used to assess whether there is a significant association between smoking status and efficacy of rosiglitazone. Up to 12 weeks No
Secondary Adverse events defined as any untoward medical occurrence in a study participant, graded using the NCI CTCAE version 3.0 Descriptively summarized in tabular form. Up to 12 weeks Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT05505539 - Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia Phase 1
Terminated NCT00176566 - A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Completed NCT04712929 - Candida Associated Cytokines in Oral Leukoplakia
Completed NCT03031899 - Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Terminated NCT00571558 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Phase 1
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting NCT04732741 - Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
Completed NCT00099021 - Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Phase 2
Not yet recruiting NCT05727761 - Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia Phase 2
Active, not recruiting NCT02581137 - Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Phase 2
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Completed NCT00330382 - Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase 2
Recruiting NCT05237960 - Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia Phase 2
Not yet recruiting NCT06256809 - Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
Completed NCT00951379 - Pioglitazone for Oral Premalignant Lesions Phase 2
Recruiting NCT04251845 - Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia N/A
Terminated NCT04079491 - Intra and Extra Oral Inspection of Oral Mucosa
Recruiting NCT00767442 - Least Invasive Nonlinear Light Microscopy N/A